ArticleNature biotechnology2019

Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy.

Jeffrey C Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.